multiple-myeloma

Drug Overview

Note: Multiple Myeloma is the name of the malignancy, not a specific medication. However, Bortezomib (Velcade®) is widely considered the cornerstone backbone therapy for this condition. This guide focuses on Bortezomib, often used in combination with other agents (like lenalidomide and dexamethasone), as the primary pharmacological intervention for Multiple Myeloma.

• Generic Name: Bortezomib
• US Brand Name: Velcade®
• Drug Class: Proteasome Inhibitor
• Route of Administration: Subcutaneous (SC) Injection or Intravenous (IV) Infusion
• FDA Approval Status: Approved (First approved in 2003)

Bortezomib is a pioneering Targeted Therapy that revolutionized the prognosis of multiple myeloma. By inhibiting the proteasome, a cellular waste disposal system, it induces cancer cell death. It is typically administered in combination regimens (e.g., VRd: Velcade, Revlimid, Dexamethasone) for both newly diagnosed and relapsed patients.

What Is It and How Does It Work? (Mechanism of Action)

Molecular Mechanism:

• Proteasome Inhibition: In normal cells, the ubiquitin-proteasome pathway regulates the concentration of intracellular proteins. Bortezomib reversibly binds to the catalytic site of the 26S proteasome, blocking its function.
• NF-κB Pathway Disruption: Multiple myeloma cells rely heavily on the NF-κB signaling pathway for survival and proliferation. Normally, an inhibitor protein (IκB) keeps NF-κB inactive. The proteasome degrades IκB, allowing NF-κB to enter the nucleus and promote cell survival. By blocking the proteasome, Bortezomib prevents the degradation of IκB.
• Apoptosis Induction: The accumulation of IκB keeps NF-κB inactive in the cytoplasm. Without the survival signals from NF-κB, and due to the accumulation of toxic protein waste (unfolded protein response), the myeloma cell undergoes cell cycle arrest and apoptosis (programmed cell death).
• Bone Microenvironment: Bortezomib also affects the bone marrow microenvironment, inhibiting the binding of myeloma cells to bone marrow stromal cells and reducing the production of growth factors (like IL-6) and angiogenesis mediators.

FDA Approved Clinical Indications

Bortezomib is FDA-approved for the treatment of adult patients with:

• Multiple Myeloma: For the treatment of patients with multiple myeloma (newly diagnosed and relapsed/refractory).
• Mantle Cell Lymphoma: For the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Dosage and Administration Protocols

Bortezomib is typically administered in cycles (e.g., 21-day or 35-day cycles). Subcutaneous administration is preferred over Intravenous due to a significantly lower risk of peripheral neuropathy.

Note: Premedication with antivirals (e.g., acyclovir) is mandatory to prevent Herpes Zoster reactivation.

Clinical Efficacy and Research Results

Bortezomib remains a key component of standard-of-care regimens in 2020-2025 guidelines.

• Newly Diagnosed Multiple Myeloma (NDMM): The SWOG S0777 trial established the VRd regimen (Bortezomib + Lenalidomide + Dexamethasone) as a standard of care. Long-term follow-up confirms significant improvements in both Progression-Free Survival (PFS) and Overall Survival (OS) compared to doublet therapy.
  • Median Overall Survival: Often exceeds 6-7 years in standard-risk patients treated with proteasome inhibitor-based induction.
• Relapsed/Refractory Disease: In the CASTOR trial (Bortezomib + Dexamethasone vs. Daratumumab + Bortezomib + Dexamethasone), the addition of the monoclonal antibody Daratumumab significantly extended median PFS (16.7 months vs. 7.1 months).
• Maintenance Therapy: While lenalidomide is the standard maintenance drug, bortezomib maintenance is supported for patients with high-risk cytogenetics (e.g., del17p, t(4;14)), improving outcomes in this difficult-to-treat population.

Safety Profile and Side Effects

Bortezomib is potent and has a distinct side effect profile, most notably affecting the nerves.

Common Side Effects (>10%)

• Neurological: Peripheral Neuropathy (numbness, tingling, burning pain in hands/feet). Significantly reduced with subcutaneous administration.
• Gastrointestinal: Nausea, diarrhea, vomiting, constipation.
• Hematological: Thrombocytopenia (low platelets), Neutropenia (low white blood cells), Anemia.
• General: Fatigue, pyrexia (fever).
• Infectious: Herpes Zoster (Shingles) reactivation.

Serious Adverse Events

• Severe Peripheral Neuropathy: Can be permanent and disabling; requires dose reduction or discontinuation.
• Cardiac Toxicity: Acute development or exacerbation of congestive heart failure.
• Pulmonary Toxicity: Acute Respiratory Distress Syndrome (ARDS) or pneumonitis (rare).
• Tumor Lysis Syndrome: Rapid breakdown of cancer cells affecting kidneys and electrolytes.
• Posterior Reversible Encephalopathy Syndrome (PRES): Rare neurological condition causing seizures and hypertension.

Management Strategies:

• Neuropathy: Switch from IV to Subcutaneous injection. Reduce dose (e.g., from 1.3 to 1.0 mg/m²) or frequency (twice weekly to once weekly). Gabapentin or pregabalin may manage symptoms.
• Shingles Prevention: Mandatory prophylaxis with Acyclovir or Valacyclovir during treatment.
• Thrombocytopenia: Monitor platelets before every dose. Hold dose if platelets <25,000/µL.

Research Areas: Immunotherapy Combinations

Bortezomib is central to Regenerative Medicine research in the context of preparing the marrow for Autologous Stem Cell Transplantation (ASCT).

• Induction Therapy: Bortezomib-based regimens (e.g., VRd or Dara-VRd) are the gold standard induction therapy used to reduce tumor burden before harvesting stem cells for transplantation.
• CAR-T Cell Therapy: Research is investigating the use of bortezomib as a bridging therapy to stabilize patients while manufacturing CAR-T cells (e.g., ide-cel, cilta-cel).
• Bispecific Antibodies: Ongoing trials (2024-2025) are evaluating combinations of bortezomib with bispecific antibodies (e.g., teclistamab) to overcome resistance in the proteasome.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Complete Blood Count (CBC): Essential to monitor platelets.
• Comprehensive Metabolic Panel: To assess liver and kidney function.
• Neurological Assessment: Baseline exam to document any pre-existing neuropathy.
• Viral Screening: Hepatitis B/C and HIV screening; history of Chickenpox/Shingles.

Precautions During Treatment

• Hydration: Maintain adequate hydration to prevent renal stress from tumor lysis.
• Infection Control: Patients are immunocompromised; fever >100.4°F (38°C) requires immediate attention.

Do’s and Don’ts List

• DO take your antiviral medication (Acyclovir) daily to prevent Shingles.
• DO report pins and needles sensations in your fingers or toes immediately; early dose adjustment prevents permanent damage.
• DON’T consume Green Tea or Vitamin C supplements in high doses on treatment days, as some studies suggest they may interfere with Bortezomib efficacy.
• DON’T dehydrate; drink plenty of fluids, especially if experiencing diarrhea.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and is intended for international patients and healthcare professionals. It does not constitute medical advice, diagnosis, or treatment. Bortezomib (Velcade®) is a prescription medication; its use must be determined by a qualified oncologist based on individual patient history and genetic profiling. Dosing, protocols, and approval status may vary by country and regulatory jurisdiction. Always consult with a healthcare provider regarding specific medical conditions and treatment options.